A pharmacokinetic study published in the journal Pharmaceutics demonstrated unique benefits of Melotime, a sustained-release melatonin from Nutriventia, according to the company’s Dr. Shefali Thanawala, head of medical science and research.

The advanced delivery technology addresses common limitations of traditional melatonin supplements, she said.

The study compared the pharmacokinetics of Melotime, a 5 mg sustained-release melatonin capsule to a standard 5 mg immediate-release formulation.

The open-label, cross-over study involved 16 healthy men and women aged 18-45 who received either the sustained-release or immediate-release melatonin, followed by a 7-day washout period. The study measured key pharmacokinetic parameters — maximum concentration (Cmax), time to reach Cmax, area under the curve, and elimination half-life.

Results showed that Melotime reported higher plasma concentration in the delayed phase from 4 to 8 hours as compared to immediate-release melatonin. And the half-life of Melotime was extended to 5.10 hours, compared to 1.01 hours for immediate-release melatonin.

“Melotime’s sustained-release design is beneficial for bioactives like melatonin, which traditionally require repeated doses due to their short half-life,” Thanawala said. “By maintaining melatonin levels over an extended period, Melotime can provide more convenient and effective support for managing sleep cycles naturally.”

Nutriventia Director Rajat Shah, added: “Further, by avoiding sharp peaks in melatonin concentration, which are common with immediate-release formulations, the study demonstrates that Melotime’s smooth, controlled release helps ensure melatonin levels remain balanced, especially during critical early morning hours, promoting safer and more consistent support for healthy sleep patterns.”